Profusa and Mayo Clinic Partner to Expand Oxygen Monitoring Applications
Event summary
- Profusa and Mayo Clinic entered a know-how agreement on February 13, 2026, to advance clinical applications of oxygen monitoring technologies.
- The collaboration aims to accelerate regulatory approval and commercialization of Profusa’s Lumee™ wearable continuous tissue oxygen monitoring product.
- Target indications include cardiovascular, renal, multi-organ, and orthopedic applications, with a focus on postoperative perfusion monitoring.
- Mayo Clinic has a financial interest in the technology and will use any revenue to support its not-for-profit mission.
- Profusa has invested over $100 million in developing its Lumee technology, which enables continuous, real-time measurement of tissue oxygen.
The big picture
This collaboration between Profusa and Mayo Clinic underscores the growing emphasis on continuous biochemistry monitoring in healthcare. The partnership aims to address unmet clinical needs and improve disease management through earlier detection and better outcomes. With over $100 million invested in the Lumee technology, Profusa is positioning itself as a key player in the digital health space, leveraging Mayo Clinic’s expertise to accelerate market adoption.
What we're watching
- Regulatory Approval
- The pace at which Profusa and Mayo Clinic can secure regulatory approval for new clinical applications of the Lumee technology.
- Market Expansion
- Whether Profusa can successfully expand the market reach of its oxygen tissue monitoring technology into new indications.
- Commercialization Success
- How the collaboration will impact the commercialization of Lumee for chronic limb-threatening ischemia (CLTI) in the U.S.
Related topics